SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 7,460,000 shares, a drop of 17.6% from the November 30th total of 9,050,000 shares. Based on an average daily trading volume, of 978,800 shares, the short-interest ratio is currently 7.6 days.
Hedge Funds Weigh In On SELLAS Life Sciences Group
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC purchased a new position in shares of SELLAS Life Sciences Group in the 2nd quarter valued at about $39,000. XTX Topco Ltd acquired a new stake in SELLAS Life Sciences Group in the third quarter valued at approximately $78,000. Virtu Financial LLC lifted its stake in SELLAS Life Sciences Group by 24.1% in the third quarter. Virtu Financial LLC now owns 79,241 shares of the company's stock worth $99,000 after acquiring an additional 15,398 shares during the last quarter. State Street Corp grew its holdings in SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company's stock worth $218,000 after acquiring an additional 40,500 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of SELLAS Life Sciences Group by 17.1% in the 3rd quarter. Geode Capital Management LLC now owns 605,191 shares of the company's stock valued at $757,000 after purchasing an additional 88,183 shares during the last quarter. Hedge funds and other institutional investors own 17.38% of the company's stock.
SELLAS Life Sciences Group Stock Down 3.0 %
NASDAQ SLS traded down $0.03 during trading on Friday, hitting $0.98. The stock had a trading volume of 1,076,535 shares, compared to its average volume of 1,116,367. SELLAS Life Sciences Group has a twelve month low of $0.50 and a twelve month high of $1.72. The firm has a 50 day moving average price of $1.12 and a 200 day moving average price of $1.19. The company has a market capitalization of $68.97 million, a PE ratio of -1.42 and a beta of 2.39.
SELLAS Life Sciences Group Company Profile
(
Get Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Recommended Stories
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
